Rethinking the Way we Fight Bacteria
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D
R&D pharmaceutical companies are currently working on 34 antibacterial compounds (19 molecules and 15 vaccines), of which 8 are undergoing the final stages of demonstrating their efficacy, quality, and safety (phase 3 clinical trials).
This report produced by leading R&D based pharmaceutical companies highlights the scientific challenges associated with the development of new antibiotics and gives recommendations for new mechanisms to stimulate antibiotic R&D that are adapted to the unique dynamics of the market for antibiotics.
Source: International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Have Your Say
Rate this feature and give us your feedback in the comments section below
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.